Article Details
Retrieved on: 2025-09-20 23:33:53
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
- Roche's subcutaneous Lunsumio gains EU and US approvals for relapsed/refractory follicular lymphoma, becoming first CD20xCD3 bispecific antibody in ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here